Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.47 |
| ▸ | ACACB | O00763 | 2/20 | 0.45 |
| ▸ | SCD | O00767 | 2/20 | 0.45 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.45 |
| ▸ | MME | P08473 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8255494 | 0.81 | MME (0.62) | ACEACE2MMELTA4H | |
| SCHEMBL5869326 | 0.81 | MME (0.62) | ACEACE2MMELTA4H | |
| SCHEMBL8258735 | 0.81 | MME (0.62) | ACEACE2MMELTA4H | |
| SCHEMBL8257978 | 0.81 | MME (0.62) | ACEACE2MMELTA4H | |
| SCHEMBL5869393 | 0.79 | HDAC1 (0.46) | ACEACE2MMELTA4H | |
| SCHEMBL8250258 | 0.79 | HDAC1 (0.46) | ACEACE2MMELTA4H | |
| SCHEMBL5869400 | 0.79 | HDAC1 (0.46) | ACEACE2MMELTA4H | |
| SCHEMBL5870075 | 0.79 | HDAC1 (0.46) | ACEACE2MMELTA4H | |
| SCHEMBL5869448 | 0.79 | HDAC1 (0.46) | ACEACE2MMELTA4H | |
| SCHEMBL3471108 | 0.78 | L3MBTL1 (0.53) | ACACBSCDSCD5L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009183-A1 | METHOD FOR TREATMENT OF PANCREATITIS | ORE PHARMACEUTICALS INC. (US) | 2012-01-12 | — | — | US | claimed |
| US-20090186014-A1 | METHOD FOR TREATMENT OF PANCREATITIS | ORE PHARMACEUTICALS INC. (US) | 2009-07-23 | — | — | US | claimed |
| WO-2009049022-A1 | METHOD FOR TREATMENT OF PANCREATITIS | ORE PHARMACEUTICALS INC. (US) | 2009-04-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186014-A1 | METHOD FOR TREATMENT OF PANCREATITIS | AMY2A, PNLIP, ACE | ACE 3/4885ACE2 6/4885ACACB 364/4885 |
| US-20120009183-A1 | METHOD FOR TREATMENT OF PANCREATITIS | AMY2A, PNLIP, ACE | ACE 3/4885ACE2 6/4885ACACB 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.